Finance Watch: Abcuro Raises $200m To See Lead Drug Through To Launch

 
• By Mandy Jackson

Private Company Edition: Abcuro’s series C venture capital round will fund its lead drug through pivotal results, filing with the US FDA and launch preparations. Also, AdvanCell completed a $112m series C round, Lutris Pharma raised $30m and Imvax closed a $29m financing.

Finance Watch Private Company
• Source: Shutterstock

More from Finance Watch

More from Scrip